biostudies-literatureUnknown5(5)Furukawa K<h4>Importance</h4>Although 2 and 3 doses of vaccine have been implemented against the SARS-CoV-2 pandemic, the level of immunity achieved by these additional vaccinations remains unclear.<h4>Objective</h4>To investigate the induction of neutralizing antibodies against the SARS-CoV-2 Omicron variant after 2 and 3 doses of the BNT162b2 messenger RNA (mRNA) vaccine among recipients of different ages.<h4>Design, setting, and participants</h4>A cohort study was conducted from June 1, 2021, to January 12, 2022, among 82 physicians at Kobe University Hospital who had received 2 doses of the BNT162b2 mRNA vaccine.<h4>Main outcomes and measures</h4>The rates of positive test results and the titers of neutralizing antibodies against the Omicron variant after 2 and 3 doses of the vaccine were comparJAMA network opene2210780https://www.ebi.ac.uk/biostudies/studies/S-EPMC9086840biostudies-literatureAssessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.PMC9086840Furukawa KMori YNishimura MArii JKurahashi YSutandhio STjan LHfalseAssessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.<h4>Importance</h4>Although 2 and 3 doses of vaccine have been implemented against the SARS-CoV-2 pandemic, the level of immunity achieved by these additional vaccinations remains unclear.<h4>Objective</h4>To investigate the induction of neutralizing antibodies against the SARS-CoV-2 Omicron variant after 2 and 3 doses of the BNT162b2 messenger RNA (mRNA) vaccine among recipients of different ages.<h4>Design, setting, and participants</h4>A cohort study was conducted from June 1, 2021, to January 12, 2022, among 82 physicians at Kobe University Hospital who had received 2 doses of the BNT162b2 mRNA vaccine.<h4>Main outcomes and measures</h4>The rates of positive test results and the titers of neutralizing antibodies against the Omicron variant after 2 and 3 doses of the vaccine were compar2022-01-01T00:00:00Z2022 May2026-05-09T23:39:41.165Z2025-04-04T19:33:27.451ZS-EPMC90868403553293810.1001/jamanetworkopen.2022.10780